EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5

EMA

30 August 2023 - The EMA’s CHMP has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant.

The vaccine – known as Comirnaty Omicron XBB.1.5 – is to be used for preventing COVID-19 in adults and children from 6 months of age.

Read EMA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Europe , Vaccine , COVID-19